Coya Therapeutics, Inc. (NASDAQ:COYA) Short Interest Up 10.2% in December

Coya Therapeutics, Inc. (NASDAQ:COYA) saw a significant growth in short interest in the month of December. As of December 31st, there was short interest totalling 209,200 shares, a growth of 10.2% from the December 15th total of 189,800 shares. Based on an average daily volume of 92,500 shares, the days-to-cover ratio is currently 2.3 days. Approximately 1.4% of the company’s shares are short sold.

Insider Buying and Selling at Coya Therapeutics

In other Coya Therapeutics news, CEO Arun Swaminathan bought 5,000 shares of Coya Therapeutics stock in a transaction on Monday, November 11th. The shares were bought at an average price of $7.34 per share, for a total transaction of $36,700.00. Following the completion of the transaction, the chief executive officer now directly owns 5,000 shares of the company’s stock, valued at $36,700. This trade represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available at this link. Insiders have acquired 9,510 shares of company stock worth $69,615 over the last quarter. 12.00% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the business. Renaissance Technologies LLC acquired a new position in shares of Coya Therapeutics during the 2nd quarter worth about $101,000. GHP Investment Advisors Inc. acquired a new position in shares of Coya Therapeutics during the 3rd quarter worth about $169,000. Finally, Geode Capital Management LLC boosted its position in shares of Coya Therapeutics by 3.3% in the 3rd quarter. Geode Capital Management LLC now owns 142,309 shares of the company’s stock valued at $918,000 after purchasing an additional 4,485 shares during the period. 39.75% of the stock is owned by institutional investors and hedge funds.

Coya Therapeutics Trading Down 3.9 %

COYA traded down $0.22 on Friday, hitting $5.38. 63,988 shares of the company were exchanged, compared to its average volume of 51,707. Coya Therapeutics has a twelve month low of $4.75 and a twelve month high of $10.69. The company has a market cap of $89.88 million, a price-to-earnings ratio of -8.28 and a beta of 0.46. The firm has a 50-day moving average price of $6.02 and a two-hundred day moving average price of $6.49.

Coya Therapeutics (NASDAQ:COYA) last released its earnings results on Wednesday, November 6th. The company reported ($0.26) EPS for the quarter, topping the consensus estimate of ($0.41) by $0.15. Equities analysts expect that Coya Therapeutics will post -1.15 EPS for the current year.

Analyst Ratings Changes

Several equities research analysts recently issued reports on COYA shares. Chardan Capital reiterated a “buy” rating and issued a $14.00 price objective on shares of Coya Therapeutics in a report on Thursday, November 7th. D. Boral Capital reiterated a “buy” rating and issued a $15.00 price objective on shares of Coya Therapeutics in a report on Wednesday, December 18th. Finally, HC Wainwright reiterated a “buy” rating and issued a $18.00 price objective on shares of Coya Therapeutics in a report on Monday, November 11th.

About Coya Therapeutics

Coya Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy.